8-K: Atossa Therapeutics Faces Patent Challenges as Intas Pharmaceuticals Files Petitions

Atossa Therapeutics is contesting Post Grant Review (PGR) and Inter Partes Review (IPR) petitions filed by Intas Pharmaceuticals against two of its patents related to Endoxifen.

Summary

• Atossa Therapeutics announced that Intas Pharmaceuticals Ltd. has filed a Petition for Post Grant Review (PGR) and a Petition for Inter Partes Review (IPR) with the U.S. Patent and Trademark Office.
• The petitions relate to Atossa's U.S. Patent No. 12,071,391 and U.S. Patent No. 11,261,151, both titled 'Methods for Making and Using Endoxifen'.
• Atossa intends to vigorously contest the PGR and IPR Petitions.
• The company believes that the Patents were properly granted and include valid and enforceable claims.
• However, there is no assurance that Atossa will prevail in contesting the PGR and IPR Petitions.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the patent challenges, creating uncertainty about Atossa's intellectual property and future prospects.

Positives

• Atossa intends to vigorously contest the PGR and IPR Petitions, indicating a strong defense strategy.

Negatives

• Intas Pharmaceuticals' PGR and IPR petitions create uncertainty regarding the validity and enforceability of Atossa's patents.
• There is no assurance that Atossa will prevail in contesting the petitions.

Risks

• The outcome of the PGR and IPR petitions could impact Atossa's intellectual property rights related to Endoxifen.
• Unsuccessful defense of the patents could negatively affect Atossa's competitive position and future revenue streams.

Future Outlook

The future outlook depends on the outcome of the PGR and IPR petitions, which will determine the validity and enforceability of Atossa's patents related to Endoxifen.

Management Comments

• Atossa believes that the Patents were properly granted and include valid and enforceable claims.

Industry Context

This announcement highlights the competitive landscape in the pharmaceutical industry, where intellectual property is crucial and patent challenges are common.

Stakeholder Impact

• Shareholders face increased risk due to the uncertainty surrounding the patent challenges.
• Employees may experience uncertainty depending on the outcome of the patent disputes and its impact on the company's future.

Next Steps

• Atossa will vigorously contest the PGR and IPR Petitions.

Key Dates

Keywords

Atossa Therapeutics, Intas Pharmaceuticals, Patent, PGR, IPR, Endoxifen, Intellectual Property